Ozempic Goes to Rehab: GLP-1s for AddictionOzempic Goes to Rehab: GLP-1s for Addiction
Addiction Medicine Made Easy
Dr Casey Grover explains how GLP-1 drugs, especially semaglutide, may help reduce alcohol use, backed by new clinical trials and real case examples. The episode also stresses compassionate care and the need to understand why each person drinks before choosing medication approaches.
30:32•24 Aug 2026
Ozempic Goes to Rehab: GLP-1s and the New Frontier in Alcohol Care
Episode Overview
- GLP-1 medications like semaglutide mimic natural gut hormones, giving a lasting feeling of fullness that can reduce both food intake and interest in alcohol.
- Three recent randomised, placebo-controlled trials suggest semaglutide can lower heavy drinking days, drinks per occasion and alcohol cravings in adults with alcohol use disorder.
- Early data hint that semaglutide may also reduce cigarette and cannabis use, though more research is needed before drawing firm conclusions.
- Combining semaglutide with other alcohol use disorder medicines, such as acamprosate, can have an additive effect on cravings for some patients.
- Medication effects vary widely, so uncovering underlying issues like PTSD, grief, anxiety or depression remains crucial in choosing the right treatment plan.
“A person struggling with addiction remains worthy of dignity, compassion, and respect.”
How do people cope with the challenges of staying sober? This episode of *Addiction Medicine Made Easy* digs into a very current question: can hugely popular GLP-1 medications like semaglutide (Ozempic/Wegovy) genuinely help with addiction, not just weight loss? Dr Casey Grover breaks things down for busy clinicians who see substance use every day in acute care.
You'll get a clear, jargon-light explanation of how GLP-1 hormones work, why they were extended from a few minutes after a meal to a week-long injection, and how that "I feel full" signal might also blunt the urge to drink or use other substances. There's even a bit of humour as he points out that these injections don’t magically turn Doritos into spinach — people just eat fewer Doritos. The heart of the episode is rapidly emerging evidence.
Three recent randomised, placebo-controlled trials of semaglutide for alcohol use disorder are discussed in detail, with concrete numbers: drops in heavy drinking days, fewer drinks per occasion, and lower cravings. Early signals around cigarette and cannabis use are mentioned, but carefully labelled as preliminary rather than game-changing. Grover keeps the conversation grounded with real-life clinic stories. One long-term binge drinker on semaglutide and acamprosate reports, "I had no idea being sober could be this easy," with cravings virtually disappearing.
Another highly educated retiree sees only a small change in drinking on semaglutide, prompting a deeper look at grief, boredom, anxiety and depression and a shift towards therapy and psychiatric support.
Threaded through the science is a strong message about dignity in care, highlighted by Dr Mario Pinole’s reflection that "a person struggling with addiction remains worthy of dignity, compassion, and respect." For clinicians curious about adding GLP-1s to their toolkit, this episode asks a bigger question: are we ready to match cutting-edge pharmacology with equally thoughtful, compassionate care for addiction?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.